FundRx.com — A 21st century model for investing in the next medical breakthrough

FundRx is shaking things up in the world of healthcare science — specifically where the theoretical rubber meets the proverbial road in patient care. Physicians with disposable capital to invest in promising new companies now have an excellent vetting resource for wisely selecting the companies they wish to back, through a peer review process that ensures only those organizations with scientifically viable concepts are seen by potential investors. Functioning like an exclusive club for serious treatment advocates who are willing to put big money behind innovative companies with the potential for making big leaps forward in healthcare delivery, FundRx is rapidly becoming a go-to platform for discriminating healthcare investors.

THE FUNDING MODEL

The funding process begins with a review by the FundRx Specialty Network, and companies they recommend are then peer-reviewed by a panel of physicians for real scientific merit. The companies that pass this peer review process are listed for investment, making it possible for FundRx members to individually contribute to those companies’ development efforts — with investments as little as $2,500. Membership is free, and there’s no obligation for members to actually contribute to any companies, so members have 100% freedom to invest as much or as little as they want toward the healthcare initiatives that seem most promising or are otherwise most important to them. Funding takes place on both a direct and indirect basis, so investors may receive shares issued by the companies they back or shares in special purpose investment vehicles that have been directed to invest in those companies.

Most of FundRx’s investors are practicing physicians who are interested in opportunities to promote their own specialty fields by supporting early- to mid-stage companies operating within their scope of practice. Investors are accredited by FundRx after demonstrating they meet a $200K minimum annual income requirement and have material stake in the healthcare sector. FundRx pays its bills through carried interest that these investors agree to relinquish in the event their shares in a company earn them a profit.

PAST AND CURRENT PROJECTS

FundRx’s portfolio of projects includes an impressive array of novel healthcare initiatives. For instance, the University of Texas has received backing for the development of Sensulin, a form of glucose-responsive insulin. SafeRide has received support for its deployment of an emerging non-emergency medical transportation network — somewhat like Uber for doctor’s appointments. Members have contributed to AthenaHealth’s SnapMD telemedicine initiative, which is helping to make mobile care management a reality for its growing user base. And Ryerson University’s Bionik Laboratories is relying on FundRx member support for its efforts to restore motor skills to individuals suffering from neurological disorders by means of pioneering robotics technology.

Investors looking for new initiatives to back have plenty of other options, too. A cursory review of current funding opportunities includes the likes of the following:

• An augmented reality app for diagnosing Alzheimer’s disease before a patient’s brain has been irreparably damaged.
• A vaccine for the common cold aimed at inoculating at-risk patients with complicating health factors.
• Smartphone apps designed to screen for and detect hearing loss in patients of various ages.
• An ultraviolet disinfection chamber for lead radiology aprons.

To be sure, it’s an exciting time for potential investors to become a part of the future in medical science. We’ll be watching FundRx with interest as a platform for propelling new blockchain applications in the healthcare sector toward wider adoption. Keep in touch for the latest developments.